肿瘤相关物质群联合检测对肺癌转移的临床诊断价值

目的　探讨肿瘤相关物质群 (TSGF)对肺癌转移和复发的诊断价值。方法　采用福建新大陆生物技术有限公司生产的TSGF快速检测诊断试剂盒对临床确诊的 75例肺癌患者 (其中局限组 39例 ,远转组 36例 )及 2 4例健康对照者血清TSGF含量进行检测 ,以TSGF≥ 6 4U/ml判断为阳性。结果　肺癌患者血清TSGF水平为 77.0 8± 15 .73U/ml( x±s) ,阳性率为 88% ,与正常对照组的 5 9.4± 4 .4 5U/ml( x±s)相比有显著差异 (P <0 .0 1)。远转组的肺癌患者的血清TSGF水平为 88.2 2± 15 .6 9U/ml,阳性率 97% ,与局限组肺癌的 6 7.5 6± 7.4 3U/ml相比亦有显著性差异 (P <0 .0 1)。结论　血清TSGF测定对肺癌的诊断有高度敏感性和特异性 ,尤其对肺癌转移的判断有临床意义     

肺癌患者血清皮质醇T_3T_4测定的临床意义

33例肺癌患者血清皮质醇水平为179.91±121.69ng/ml;54例正常人组104.28±44.23ng/ml,肺癌组显著高于正常人组。18例肺癌恶病质(A组)血清T_3水平为0.63+0.27ng/ml;15例肺癌一般状况好组(B组)血清T_3水平1.47±0.49ng/ml;132例正常人组血清T_3水平1.24±0.40ng/ml。A组明显低于B组及正常人组(P<0.01);B组与正常人组无显著差异。A组血清T_4水平为7.73+3.23μg/dl;B组血清T_48.28±22.4μg/dl;正常人组血清T_49.43±2.64μg/dl,各组之间无显著差异(P>0.05)。本文探讨了肺癌患者血清皮质醇T_3、T_4的临床意义。     

呼吸系疾病患者血清神经节苷脂与癌胚抗原

目的:研究呼吸系疾病患者血清神经节苷脂(gangliosides,GLS)与癌胚抗原(car-cinoembryonicantigen,CEA)含量及意义。方法:测定患者血清GLS、CEA,分组统计分析。结果:恶性肿瘤、结核、肺炎、慢性支气管炎组血清GLS含量分别为(908±300)、(755±316)、(820±294)、(570±147)mg/L;阳性率分别为87·8%、42·8%、61·1%和23·4%。四组血清CEA含量分别为(19·3±20·1)、(10·7±5·6)、(11·7±8·4)和(10·9±9·9)μg/L;阳性率分别为39·1%、20·0%、13·9%和18·8%。恶性肿瘤组中肺癌患者GLS含量及阳性率呈现未分化癌>鳞癌>腺癌,CEA正相反。GLS和(或)CEA阳性在恶性肿瘤组占92·2%,可作肺癌初筛指标;GLS和CEA阳性在恶性肿瘤组占34·8%,在非癌各组总计占5·8%,可作肺癌诊断指标。结论:肺癌患者血清GLS显著增加,对肺癌诊断有一定意义;GLS与CEA联合检测对肺癌诊断可能更有价值。     

血清CYFRA21-1在鼻咽癌诊断中的临床应用

[目的]探讨血清CYFRA21 1对鼻咽癌的临床实用价值。[方法]采用IRMA法测定104例鼻咽癌患者、34例鼻咽其他疾病患者和65例健康对照者的血清CYFRA21 1含量。[结果]鼻咽癌组患者血清CYFRA21 1水平(5 48±6.12)ng/ml明显高于鼻咽其他疾病组(1.45±0.86)ng/ml及健康对照组(1.17±0.98)ng/ml,差异十分显著(P<0 001) ;并且鼻咽癌患者血清CYFRA21 1水平与其分期呈正相关(r=0 4341 ,t=4.87,P<0 001)。[结论]血清CYFRA21 1对鼻咽癌的诊断、分期、监测病情变化及与恶性淋巴瘤等其他疾病鉴别方面具有较高的临床实用价值。     

急性白血病患者血清中可溶性Fas配基含量的变化

目的　探讨急性白血病患者血清可溶性Fas配基 (sFasL )的水平及其临床意义。方法　采用酶联免疫吸附试验(ELISA)对 5 0例急性白血病患者的血清sFasL含量进行检测 ,比较不同病理状态急性白血病患者血清sFasL水平的变化。结果血清sFasL含量 :初治急性淋巴细胞白血病 (ALL)为 (0 .2 4± 0 .0 8)ng/ml ,急性髓性白血病 (AML )为 (0 .2 3± 0 .11)ng/ml;未缓解/复发组ALL为 (0 .2 3± 0 .0 9)ng/ml,AML为 (0 .2 1± 0 .0 8)ng/ml ;与完全缓解 /部分缓解组ALL的 (0 .15± 0 .0 6)ng/ml、AML的 (0 .15± 0 .0 5 )ng/ml及正常对照组的 (0 .13± 0 .0 5 )ng/ml相比 ,除AML未缓解 /复发与完全缓解 /部分缓解组相比无显著性差异 (P >0 .0 5 )外 ,其余均有非常显著性差异 (P <0 .0 1)。血清sFas水平与急性白血病未缓解或复发相关。结论　血清sFasL含量的测定可用于评估急性白血病的病理状态、化疗效果及预后     

肺癌患者免疫功能变化的初步研究

目的 :通过测定肺癌患者外周血清白细胞介素 8(interleukin 8、IL 8)、白细胞介素 10 (interleukin 10、IL 10 )和转化生长因子 β1(transforminggrowthfactor β1,TGF β1)的水平 ,探讨肺癌患者的免疫功能变化及IL 8、IL 10和TGF β1在肺癌形成过程中的可能作用。方法 :用酶联免疫吸附法 (ELISA法 )测定 32例肺癌患者及 2 0例健康人血清IL 8、IL 10和TGF β1水平。统计学处理用两样本均数的t检验和方差分析。结果 :肺癌组血清IL 8、IL 10和TGF β1水平分别为 10 3.91± 30 .80pg/ml、5 0 .46± 13.18pg/ml、48.6 2± 9.35ng/ml。健康对照组血清IL 8、IL 10和TGF β1水平分别为 5 2 .5 6± 8.40pg/ml、2 8.49± 2 .85pg/ml、2 6 .89± 4.83ng/ml。结果 :肺癌组IL 8、IL 10和TGF β1水平明显高于健康对照组 ,差异有显著性 (P <0 .0 1) ,且血清IL 8、IL 10和TGF β1水平与其病理分型无关 (P >0 .0 5 ) ,与肺癌的TNM分期有关 ,随肺癌的进展各项指标的水平逐步增高 (P <0 .0 1)。结论 :上述结果提示 ,肺癌患者存在免疫功能异常 ,IL 8、IL 10和TGF β1可能在肺癌的发生、发展过程中起着一定作用。动态观察IL - 8、IL 10和TGF - β1水平将有助于肺癌的诊断及疗效评价     

肺癌血清CA125测定的诊断价值

目的探索血清CA125在肺癌诊断中的价值.方法检测69例肺癌、38例良性肺疾病和25例健康人的血清CA125.随访40例肺癌患者治疗后血清CA125的变化.结果肺癌组血清CA125(124.9±175.9 u/ml)高于良性疾病组和健康人组(28.1±21.7 u/ml,18.2±7.1 u/ml).以CA125>35u/ml为阳性界值,则正常健康人均为阴性.对诊断肺癌的敏感性为53.6%(37/69).Ⅰ、Ⅱ期肺癌血清CA125阳性率(20%,28%)与良性疾病组(15.8%)无显著差异,Ⅲ、Ⅳ期肺癌CA125阳性率分别为61.0%、72.7%显著高于良性疾病组.血清CA125增高的40例肺癌患者经治疗后,CA125浓度降至正常范围内者38例.结论血清CA125对晚期肺癌有诊断价值.可作为判断预后的参考指标.     

中、晚期恶性肿瘤TSGF的检测研究

目的　探讨中、晚期恶性肿瘤患者血清TSGF的检测价值。方法　对 119例健康人群及 15 4例临床病理确诊为Ⅲ期以上中晚期恶性肿瘤患者进行血清TSGF检测。结果　健康体检组正常值为 5 9.1± 4.68u/ml(<68u/ml为阴性 ,68～ 72u/ml为可疑阳性 ,>72u/ml为阳性 )。中晚期恶性肿瘤测得血清TSGF值为 70 .0± 13 .7u/ml,与健康对照组有显著差异性P <0 .0 1,特异度为 95 .8% ,敏感度为 49.4%。结论　检测中晚期恶性肿瘤患者血清TSGF具有临床应用价值 ,对肝癌、恶性胸腺瘤、肺癌、恶性淋巴瘤敏感度较高 ,有一定的临床应用价值。     

原发性肺癌患者外周血内皮抑素检测意义

目的 :研究原发性肺癌患者外周血内皮抑素 (endostatin)的含量水平与肺癌临床病理因素的关系。方法 :用ELISA法对 79例原发性肺癌、8例肺部良性疾病及 2 0例健康人血浆内皮抑素含量进行分析。结果 :血浆内皮抑素含量在原发性肺癌、肺部良性疾病及健康人分别为 (9 3± 5 7)pg mL、(6 3±2 5 )pg mL、(4 9± 3 2 )pg mL ,肺癌明显高于肺部良性疾病和健康人 ,P <0 0 5 ;血浆内皮抑素含量在Ⅰ、Ⅱ、Ⅲ、Ⅳ期肺癌中分别为 (6 6± 4 3)pg mL、(7 1± 5 5 )pg mL、(8 7± 6 0 )pg mL、(10 6± 4 5 )pg mL ,血浆内皮抑素含量与肺癌临床分期有关 ,P <0 0 5 ;年龄≥ 6 0岁肺癌患者血浆内皮抑素含量为 (7 9± 4 2 )pg mL ,年龄 <6 0岁为 (10 4± 5 6 )pg mL ,后者明显高于前者 ,P <0 0 1。结论 :原发性肺癌患者外周血内皮抑素含量水平显著高于正常对照 ,且与肿瘤分期和淋巴结转移有关     

乳腺癌患者血清中肿瘤相关物质群的水平

 目的　探讨乳腺癌患者血清TSGF水平及其临床意义。方法　用光电比色法检测 2 0 0例乳腺癌患者及健康对照 6 6人的血清TSGF水平。结果　初治、治疗无效及复发转移患者的血清TSGF水平分别为 (6 7.5± 4 .9)U/ml、(6 7.5± 4 .7)U/ml及 (6 5 .5± 9.6 )U/ml,均明显高于治疗显效组的 (5 5 .9±5 .1)U/ml及对照组的 (5 5 .5± 5 .3)U/ml(P <0 .0 1) ;局部复发、转移者血清TSGF水平分别为 (6 5 .0±9.8)U/ml、(6 6 .2± 9.1)U/ml,其差异无统计学意义 (P >0 .0 5 ) ;以 6 4U/ml为阳性阈值 ,TSGF检测乳腺癌的灵敏度及特异度分别为 6 0 .3%、98.5 %。结论　检测血清TSGF水平对乳腺癌的疗效及预后判断有良好效果。     

内皮抑素在肺癌患者外周血清及支气管肺泡灌洗液中的表达研究

 目的 探讨内皮抑素（Endostatin）在肺癌患者外周血清及支气管肺泡灌洗液（Bronchoalveolar lavage fluid，BALF）中的表达以及与肺癌临床病理生理特征的关系。方法 采用酶联免疫吸附法（Enzyme-linked immunosorbent assay，ELISA）检测初诊肺癌47例及肺良性病变18例患者外周血清及BALF中Endostatin的表达水平。结果 肺癌患者外周血清及BALF中Endostatin分别为（131．71±50．32）ng／ml和（502．56±302．00）ng／ml，显著高于肺良性病变者（P〈0．01）；肺癌晚期、有淋巴结及远处转移、肺腺癌患者外周血清及BALF中Endostatin高表达；肺癌患者Endostatin在外周血清及灌洗液中的表达呈线性正相关（P=0．000）。结论 检测外周血清及支气管肺泡灌洗液中Endostatin均有助于肺癌的诊断及较好提示其生物学行为。     

The value of carcinoembryonic antigens in patients with advanced lung cancer: in relation to chemotherapy

The serum carcinoembryonic antigens (CEA) levels in 177 advanced lung cancer patients were studied to assess their value for the prognosis and indicating the effectiveness of chemotherapy. The relationship of pretreatment CEA levels with histology and stage of disease was also examined. Levels in excess of 5 ng/ml and 20 ng/ml were found in 55% and 32% of lung cancer patients, respectively. The elevated CEA levels were more frequently observed in patients with adenocarcinoma (65% in excess of 5 ng/ml) and extensive disease, but pretreatment CEA levels were not significantly correlated with the histology and clinical stage of disease. In 102 patients with adenocarcinoma, there was no significant difference of survival time in each patient with CEA levels less than 5 ng/ml, 5.0 less than or equal to - less than 20 ng/ml and in excess of 20 ng/ml; median survival time was 7, 7, 8 mo, respectively, and response to chemotherapy was not significant in each of these groups. Serial serum CEA measurements in patients with pretreatment levels in excess of 20 ng/ml correlated well with changes in disease status reflecting clinical response to chemotherapy. Mean percent changes of CEA levels to pretreatment levels were-77.4% in patients with partial response (PR), -55.6% in those with minor response (MR), -4.0% in patients with no change (NC) and +79.0% in patients showing progressive disease (PD). There was a significant difference in the percent changes of CEA levels between patients with an objective response (PR) and patients who had none (MR + NC) (p less than 0.02). CEA levels of all patients who had PD increased or unchanged. Serial measurements of serum CEA are useful in patients whose pretreatment levels are more than 20 ng/ml for monitoring the response to chemotherapy, and may be a useful noninvasive technique for patients with unmeasurable disease as a monitor of tumor burden in response to chemotherapy and recurrent disease.     

Serum and bronchial aspiration fluid HE-4 levels in lung cancer

Human epididymis 4 (HE-4) protein has been proposed as a tumor marker for lung and ovarian cancer. This study was designed to measure HE-4 levels in bronchial aspiration fluid (BAF) of patients with lung cancer and to describe the relationship of BAF HE-4 with known systemic increase in serum HE-4 levels. Sixty-four patients with lung cancer, 38 with benign lung disease and 19 healthy subjects, were enrolled in our study. The BAF was obtained during routine bronchoscopic procedure in patient groups. HE-4 levels in serum and BAF were measured with the commercially available kit by an enzyme-linked immunosorbent assay. Serum HE-4 levels were significantly higher in patients with lung cancer group (204.2?±?22.9 pmol/L) than in benign lung disease group (135?±?26.9 pmol/L, p?=?0.001) and healthy subjects (14.8?±?7.0 pmol/L, p?p?p?=?0.001) and age (p?相似文献   

Serum HE4 as a diagnostic and prognostic marker for lung cancer

We evaluated the diagnostic and prognostic efficacy of human epididymis protein 4 (HE4) for lung cancer patients by using our novel enzyme-linked immunosorbent assay (ELISA) system. We measured serum HE4 levels of cancer patients including 49 lung cancer and 18 ovarian cancer patients. Furthermore, we evaluated the relationship between serum HE4 levels and overall survival after chemotherapy of 24 lung cancer patients. Serum HE4 levels were significantly higher for non-small, small cell lung cancer and ovarian cancer patients than for healthy controls. The area under the receiver operating characteristic curve (AUC) was calculated for differentiation of lung cancer patients and healthy controls. AUC for serum HE4 was 0.988 for differentiating lung cancer patients from healthy controls, with a cutoff value of 6.56 ng/ml (sensitivity = 89.8%, specificity = 100%). Serum HE4 levels were elevated in 36/40 (90.0%) non-small cell lung cancer patients, 8/9 (88.9%) small cell lung cancer patients and 8/18 (44.4%) ovarian cancer patients. High levels of serum HE4 (>15 ng/ml) after chemotherapy were significantly correlated with worse overall survival after the treatment. These findings suggest that serum HE4 is a potential diagnostic and prognostic marker for lung cancer patients.     

Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans

Over-expression of the c-erbB-2 oncogene-encoded p185 protein product has been implicated in the pathogenesis of a wide variety of human malignancies, including lung cancer. Over-expression of p185 can be detected immunologically by quantification of the extracellular domain of p185 (c-erbB-2 oncopeptide) in extracellular fluid in vitro and in serum in vivo. An enzyme-linked immunosorbent assay (ELISA) for the c-erbB-2 oncopeptide was used to examine banked serum samples of 11 pneumoconiosis patients who subsequently developed lung cancer and serum samples from 11 hospital controls matched for age, sex, ethnic group and smoking as well as 55 unmatched general population controls. The mean serum level for the c-erbB-2 oncopeptide in human neu units/ml in the lung cancer cases (1,756 ± 549 HNU/ml) was statistically significantly elevated (p < 0.001) in comparison to the mean level in the matched controls (976 ± 488 HNU/ml) or the general population controls (888 ± 655 HNU/ml). Defining a positive elevation of the serum c-erbB-2 oncopeptide as any value more than 2 standard deviations above the mean of the matched controls, 64% (7 of 11) of the lung cancer cases were positive compared to 0% (0 of 11) matched controls and 5% (3 of 55) of the unmatched controls. In addition, 4 of the 7 c-erbB-2 oncopeptide-positive cancer cases had positive serum samples prior to the time of disease diagnosis (average = 35 months). These results suggest that serum c-erbB-2 oncopeptide may be elevated at an early stage of pulmonary carcinogenesis and that further prospective study of the utility of this biomarker is warranted.     

Elevated serum epidermal growth factor receptor level is correlated with lymph node metastasis in lung cancer

Background: Using an enzyme immunoassay for epidermal growth factor receptor (EGFR), we investigated whether serum EGFR levels could be used as predictors of the development and extent of lung cancer. Methods: The study included 106 lung cancer patients and 16 patients with nonmalignant thoracic disease. Serum samples were collected before clinical treatment. Results: There was no difference between serum EGFR levels in patients with lung cancer (21.275 ± 22.035 fm/ml) in comparison with those in nonmalignant-disease controls (22.630 ± 7.330 fm/ml; P = 0.8083). However, lung cancer patients with lymph node metastasis (23.515 ± 20.065 fm/ml) had significantly higher EGFR levels compared with those in patients without lymph node metastasis (16.390 ± 10.970 fm/ml; P = 0.0228). The serum EGFR levels were similar in samples from lung cancer patients with various pathological subtypes. There was no difference in the prognosis between the lung cancer group with normal EGFR levels (<850 ng/ml) and the group with elevated EGFR levels (>850 ng/ml). Conclusion: Serum EGFR levels may serve as a marker that can be used as an indicator of lymph node metastasis in lung cancer. However, there was no difference between levels in patients with lung cancer and those in nonmalignant-disease controls, indicating that the measurement of serum EGFR levels was of limited value in the detection of lung cancer. Received: April 18, 2002 / Accepted: January 6, 2003 Correspondence to:H. Sasaki     

肺癌热化疗患者IL-2、TNF、IGF的表达

 目的 探讨热疗联合化疗治疗非小细胞肺癌（NSCLC）对白细胞介素-2（IL-2）、肿瘤坏死因子（TNF）、胰岛素样生长因子（IGF）的影响。方法 回顾性分析2003年9月至2006年10月收治的67例NSCLC，进行微波热疗、NP方案化疗联合治疗，同时监测血清中IL-2、TNF、IGF的变化。结果 IL-2热化疗组与对照组治疗前分别为（3.68±0.49）ng／ml、（3.32±0.42）ng／ml；治疗后1个月（10.40±1.71）ng／ml、（4.41±0.48）ng／ml。TNF热化疗组、对照组治疗前（2.21±0.36）ng／ml、（2.21±0.19）ng／ml；治疗后1个月（7.83±0.55）ng／ml、（3.68±0.60）ng／ml。IGF热化疗组、对照组治疗前（79.40±3.84）ng／ml、（78.91±3.18）ng／ml；治疗后1个月（36.51±2.11）ng／ml、（52.22±3.18）ng／ml。热化疗组患者的近期疗效明显好于对照组。结论 热化疗对IL-2、TNF有明显的增高作用，而对IGF有降低作用；热化疗治疗肿瘤疗效肯定。     

Spermidine radioimmunoassay in monitor of precancerous lesions of esophagus

Serum spermidine was assayed by radioimmunoassay in different stages of esophageal carcinogenesis in the population from high risk area of esophageal cancer, Linxian County. The serum spermidine values were 76.94±74.38 ng/ml in 36 normal individuals; 115.71±113.45 ng/ml in 35 patients with marked epithelial hyperplasia (MEH) and 294.48±135.36 ng/ml in 31 patients with early esophageal cancer. Patients with MEH were given intervention treatment by Aminoretinoic Ester or Anticancer B or placebo (starch) as controls. One year later, samples from the population were collected again for serum spermidine measurement. The values were 95.8+68.2 ng/ml in 27 normals; 125.1±72.9 ng/ml in 62 patients with MEH treated by Anticancer B; 125.6±117.2 ng/ml in 64 patients with MEH treated by Aminoretinoic Ester; 162.4±76.6 ng/ml in 62 controls and 210.5±182.9 ng/ml in 44 patients with early esophageal cancer. The results showed that spermidine radioimmunoassay could reflect the tendency of esophageal precancerous changes toward cancer or back to nromal. They can be taken as a mid-way monitor indicator for tumor-blocking drugs. Also, it could be of value in the early diagnosis of esophageal cancer.     

Percutaneous microwave ablation (MWA) increased the serum levels of VEGF and MMP-9 in Stage I non-small cell lung cancer (NSCLC)

Background: Lung cancer is the leading cause of cancer death around the world. Percutaneous microwave ablation (MWA) is an emerging treatment strategy for medically inoperable early-stage non-small cell lung cancer (NSCLC). In this study, we investigated the association of MWA and serum angiogensis promoters VEGF and MMP-9 in these patients subgroup.

Methods: We enrolled 52 patients with Stage I NSCLC patients in this study. For each patient, blood samples were drawn by venous puncture, one immediately prior to MWA and the others on Post-Procedure Days (PPD) 1, 3, 5, 7, 10 and 14. Serum samples were analysed for VEGF and MMP-9 levels with use of commercially available enzyme-linked immunosorbent assay. Also, blood samples of 28 healthy volunteers were set as the healthy controls.

Results: We did not observe a significant difference of serum VEGF and MMP-9 between NSCLC patients and healthy controls. The VEGF levels increased on the first day (256.0?±?6.16?pg/ml, p?p?p?p?p?p?>?0.05). The highest MMP-9 level was observed on PPD5 (399.7?±?17.70?ng/ml, p?Conclusion: Our preliminary results indicated that percutaneous MWA resulted in increased serum levels of VEGF and MMP-9 in Stage I NSCLC patients. Antiangiogenesis approaches may be helpful for patients defending against metastases during the immediate post-ablation time window.     

Carcinoembryonic Antigen (CEA) Levels in Pleural Effusions and Sera of Lung Cancer Patients

For determining the value of carcinoembryonic antigen (CEA)levels in diagnosis of malignant tumors of the lung, the CEAlevels in 187 specimens of pleural fluid and sera obtained simultaneouslyfrom patients with pleural fluid were measured. In all 70 patientswith benign diseases, the CEA levels in the effusions were lessthan the cut-off value of 5 ng/ml (mean±SD: 1.44±1.01ng/ml). In contrast, in 88 of 117 patients (75.2%) with malignantdiseases, the CEA levels in the effusions were over 5 ng/ml(25.3±24.5 ng/ml) and in 58 of the 117 patients (50.4%),the CEA levels in the serum were values of 5 ng/ml or more (11.9±18.4ng/ml). There was a significant correlation between the CEAlevels in the effusions and in the sera. The CEA levels in effusionsin patients with malignant lung tumors were usually much higherthan those in their sera. The incidence of CEA levels of 5 ng/mlor more in both the serum and effusion was highest in the patientswith adenocarcinoma. These data indicate that determination of the CEA level in effusions,when done in combination with cytological examinations, mayhave additional value in diagnosis of lung cancer.